<DOC>
	<DOCNO>NCT00679497</DOCNO>
	<brief_summary>The purpose clinical trial study modify pox viral vector consider : 1 . HIV subtype B account frequent virus strain Europe North America , well many part world . 2 . This novel vaccinia construct express HIV subtype B gag , pol , env nef antigen study human first time .</brief_summary>
	<brief_title>A Phase I Study Modified Vaccinia Virus Ankara ( MVA-B ) Healthy Volunteers Low Risk HIV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>male female age 18 55 year day screen available followup duration study ( 52 week screen ) able give write informed consent low risk HIV willing remain duration study low risk HIV infection define : history inject drug use previous ten year gonorrhoea syphilis last six month high risk partner ( e.g . inject drug use , HIV positive partner ) either currently within past six month unprotected anal intercourse last six month unprotected vaginal intercourse outside relationship regular known/presumed HIV negative partner last six month willing undergo HIV test willing undergo genital infection screen heterosexually active female , use effective method contraception partner ( combined oral contraceptive pill ; injectable contraceptive ; IUCD ; consistent record condom use ; physiological anatomical sterility self partner ) 14 day prior first vaccination 4 month last , willing undergo urine pregnancy test prior vaccination heterosexually active male , use effective method contraception partner first day vaccination 4 month last vaccination positive hepatitis B surface antigen , hepatitis C antibody , antibody response vaccinia serology indicate active syphilis require treatment pregnant lactate clinically relevant abnormality history examination include history grandmal epilepsy , severe eczema , immunodeficiency use immunosuppressives precede 3 month receipt live attenuate vaccine within 60 day vaccine within 14 day enrolment receipt blood product immunoglobin within 4 month screen participation another trial medicinal product , complete less 30 day prior enrolment history severe local general reaction vaccination define local : extensive , indurated redness swell involve frontlateral thigh major circumference arm , resolve within 72 hour general : fever &gt; = 39.5oC within 48 hour ; anaphylaxis ; bronchospasm ; laryngeal HIV 1/2 positive indeterminate screen positive hepatitis B surface antigen , hepatitis C antibody serology indicate active syphilis require treatment grade 1 routine laboratory parameter unlikely comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Low risk HIV infection</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>